SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 14, 2011
DORAL FINANCIAL CORPORATION
(Exact name of registrant as specified in its charter)
1451 Franklin D. Roosevelt Avenue, San Juan, Puerto Rico 00920-2717
(Address of Principal Executive Offices, Including Zip Code)
Registrants telephone number, including area code: 787-474-6700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 14, 2011, Doral Financial Corporation (the Company) was notified by the New York Stock Exchange, Inc. (the NYSE) that the average per share closing price of its common stock during the 30 trading-day period ending December 12, 2011 was below the NYSEs continued listing standard relating to minimum average closing share price. Rule 802.01C of the NYSEs Listed Company Manual provides that the Company will be considered to be below compliance standards if the average closing price of the Companys common stock is less than $1.00 over a consecutive 30 trading-day period.
Under the applicable rules of the NYSE, the Company has 10 business days from receipt of the notice to inform the NYSE that it intends to cure the deficiency. The Company intends to notify the NYSE that it intends to cure the deficiency within the prescribed timeframe. The Company has six months from receipt of the notice to regain compliance with the NYSEs price condition and bring its share price and average share price back above $1.00 per share. The Company can regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period.
Subject to the NYSEs rules, during the cure period, shares of the Companys common stock will continue to be listed and will trade on the NYSE, subject to the Companys continued compliance with the NYSEs other applicable listing rules. The Company is currently in compliance with all other NYSE listing rules.
If the Company effectuates a reverse stock split vote at its next annual meeting of stockholders to cure the condition, the condition will be deemed cured if the price promptly exceeds $1.00 per share, and the price remains above the level for at least the following 30 trading days.
As required under NYSE rules, the Company issued a press release on December 16, 2011, announcing that it had received the notice of non-compliance and that the Company intends to cure the deficiency within the prescribed timeframe. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.